MedTrace Logo

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

NCT03408093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2018-06-21

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) who had more than 6 months in treatment.

Conditions

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-03
Primary Completion
2010-03-30
Completion
2010-03-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03408093 on ClinicalTrials.gov